For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.

The General Pharmaceutical Council (GPhC) has introduced new rules for weight-loss jabs, such as Wegovy and Mounjaro, in ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

Medically reviewed by Jonathan Purtell, RDN Walmart is the largest full-service grocery store in the United States. It offers ...

A large cohort study examining more than 125,000 adults in the U.S. found that the majority of patients discontinue GLP-1 RA therapy within the first year, with those without Type 2 diabetes showing ...

Tariffs and price inflation for specialty medications will increase costs, according to research from Vizient.

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.

An hour of moderate-intensity exercise reduced sensations of hunger in people with overweight and obesity in a recent study.

A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.